Bristol Myers Squibb Company appears ready to file for approval of an early-stage non-small cell lung cancer indication with Opdivo, a potentially important milestone as it battles with Merck & Co., Inc. for earlier-stage cancer settings for their checkpoint inhibitors. But as the first neoadjuvant treatment for NSCLC, it will have to prepare the market.
BMS Prepares To Move Opdivo Into Neoadjuvant Lung Cancer
BMS reports event-free survival advantage, adding to earlier findings that Opdivo plus chemotherapy met statistical significance for pathologic complete response in the CheckMate-816 study.
More from Immuno-oncology
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
Increasingly focused on maximizing and accelerating the progress of its PD-L1 x VEGF inhibitor BNT357, the company expects new partnerships to be announced this year.
More from Anticancer
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares